1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Prescription Weight Loss Medications Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Prescription Weight Loss Medications Market, by Drug Class
8.1.1. GLP-1 Receptor Agonists
8.1.1.1. Market Revenue and Forecast
8.1.2. Combination Therapies
8.1.2.1. Market Revenue and Forecast
8.1.3. Appetite Suppressants/Other Pharmacotherapies
8.1.3.1. Market Revenue and Forecast
8.1.4. Emerging/Next-Gen Agents
8.1.4.1. Market Revenue and Forecast
9.1. Prescription Weight Loss Medications Market, by Route of Administration
9.1.1. Injectable Medications
9.1.1.1. Market Revenue and Forecast
9.1.2. Oral Medications
9.1.2.1. Market Revenue and Forecast
10.1. Prescription Weight Loss Medications Market, by Prescription Type
10.1.1. Specialist Prescriptions (Endocrinologists / Obesity Specialists)
10.1.1.1. Market Revenue and Forecast
10.1.2. General Practitioner Prescriptions
10.1.2.1. Market Revenue and Forecast
11.1. Prescription Weight Loss Medications Market, by Indication
11.1.1. Obesity Management
11.1.1.1. Market Revenue and Forecast
11.1.2. Weight Loss with Comorbid Condition (T2D, CVD risk)
11.1.2.1. Market Revenue and Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Drug Class
12.1.2. Market Revenue and Forecast, by Route of Administration
12.1.3. Market Revenue and Forecast, by Prescription Type
12.1.4. Market Revenue and Forecast, by Indication
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Drug Class
12.1.5.2. Market Revenue and Forecast, by Route of Administration
12.1.5.3. Market Revenue and Forecast, by Prescription Type
12.1.5.4. Market Revenue and Forecast, by Indication
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Drug Class
12.1.6.2. Market Revenue and Forecast, by Route of Administration
12.1.6.3. Market Revenue and Forecast, by Prescription Type
12.1.6.4. Market Revenue and Forecast, by Indication
12.2. Europe
12.2.1. Market Revenue and Forecast, by Drug Class
12.2.2. Market Revenue and Forecast, by Route of Administration
12.2.3. Market Revenue and Forecast, by Prescription Type
12.2.4. Market Revenue and Forecast, by Indication
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Drug Class
12.2.5.2. Market Revenue and Forecast, by Route of Administration
12.2.5.3. Market Revenue and Forecast, by Prescription Type
12.2.5.4. Market Revenue and Forecast, by Indication
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Drug Class
12.2.6.2. Market Revenue and Forecast, by Route of Administration
12.2.6.3. Market Revenue and Forecast, by Prescription Type
12.2.6.4. Market Revenue and Forecast, by Indication
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Drug Class
12.2.7.2. Market Revenue and Forecast, by Route of Administration
12.2.7.3. Market Revenue and Forecast, by Prescription Type
12.2.7.4. Market Revenue and Forecast, by Indication
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Drug Class
12.2.8.2. Market Revenue and Forecast, by Route of Administration
12.2.8.3. Market Revenue and Forecast, by Prescription Type
12.2.8.4. Market Revenue and Forecast, by Indication
12.3. APAC
12.3.1. Market Revenue and Forecast, by Drug Class
12.3.2. Market Revenue and Forecast, by Route of Administration
12.3.3. Market Revenue and Forecast, by Prescription Type
12.3.4. Market Revenue and Forecast, by Indication
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Drug Class
12.3.5.2. Market Revenue and Forecast, by Route of Administration
12.3.5.3. Market Revenue and Forecast, by Prescription Type
12.3.5.4. Market Revenue and Forecast, by Indication
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Drug Class
12.3.6.2. Market Revenue and Forecast, by Route of Administration
12.3.6.3. Market Revenue and Forecast, by Prescription Type
12.3.6.4. Market Revenue and Forecast, by Indication
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Drug Class
12.3.7.2. Market Revenue and Forecast, by Route of Administration
12.3.7.3. Market Revenue and Forecast, by Prescription Type
12.3.7.4. Market Revenue and Forecast, by Indication
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Drug Class
12.3.8.2. Market Revenue and Forecast, by Route of Administration
12.3.8.3. Market Revenue and Forecast, by Prescription Type
12.3.8.4. Market Revenue and Forecast, by Indication
12.4. MEA
12.4.1. Market Revenue and Forecast, by Drug Class
12.4.2. Market Revenue and Forecast, by Route of Administration
12.4.3. Market Revenue and Forecast, by Prescription Type
12.4.4. Market Revenue and Forecast, by Indication
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Drug Class
12.4.5.2. Market Revenue and Forecast, by Route of Administration
12.4.5.3. Market Revenue and Forecast, by Prescription Type
12.4.5.4. Market Revenue and Forecast, by Indication
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Drug Class
12.4.6.2. Market Revenue and Forecast, by Route of Administration
12.4.6.3. Market Revenue and Forecast, by Prescription Type
12.4.6.4. Market Revenue and Forecast, by Indication
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Drug Class
12.4.7.2. Market Revenue and Forecast, by Route of Administration
12.4.7.3. Market Revenue and Forecast, by Prescription Type
12.4.7.4. Market Revenue and Forecast, by Indication
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Drug Class
12.4.8.2. Market Revenue and Forecast, by Route of Administration
12.4.8.3. Market Revenue and Forecast, by Prescription Type
12.4.8.4. Market Revenue and Forecast, by Indication
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Drug Class
12.5.2. Market Revenue and Forecast, by Route of Administration
12.5.3. Market Revenue and Forecast, by Prescription Type
12.5.4. Market Revenue and Forecast, by Indication
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Drug Class
12.5.5.2. Market Revenue and Forecast, by Route of Administration
12.5.5.3. Market Revenue and Forecast, by Prescription Type
12.5.5.4. Market Revenue and Forecast, by Indication
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Drug Class
12.5.6.2. Market Revenue and Forecast, by Route of Administration
12.5.6.3. Market Revenue and Forecast, by Prescription Type
12.5.6.4. Market Revenue and Forecast, by Indication
13.1. Novo Nordisk
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Eli Lilly and Company
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Pfizer Inc.
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Amgen Inc.
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. GlaxoSmithKline (GSK) plc.
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. AstraZeneca
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Rhythm Pharmaceuticals
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. F. Hoffmann-La Roche Ltd
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Currax Pharmaceuticals LLC
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Viking Therapeutics Inc.
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
